

# CLINUVEL

## ASX ANNOUNCEMENT

Melbourne, Australia, 16 October 2024

ASX: CUV | Börse Frankfurt: UR9 | ADR Level 1: CLVLY

## Results of AGM

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions, and the proxies received in respect of each resolution are set out in the attached proxy summary.

Yours faithfully,

Claire Newstead-Sinclair

Company Secretary

– END –

### About CLINUVEL PHARMACEUTICALS LIMITED

CLINUVEL (ASX: CUV; ADR LEVEL 1: CLVLY; Börse Frankfurt: UR9) is a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialised populations. As pioneers in photomedicine and the family of melanocortin peptides, CLINUVEL's research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, assisted DNA repair, repigmentation and acute or life-threatening conditions who lack alternatives.

CLINUVEL's lead therapy, SCENESSE® (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the world's first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore, and the USA. For more information, please go to <https://www.clinuvel.com>.

**Authorised for ASX release by the Board of Directors of CLINUVEL PHARMACEUTICALS LTD.**

### Head of Investor Relations

Mr Malcolm Bull, CLINUVEL PHARMACEUTICALS LTD

### Investor Enquiries

<https://www.clinuvel.com/investors/contact-us>

### Contact:

Tel: +61 3 9660 4900

Fax: +61 3 9660 4909

Email: [mail@clinuvel.com](mailto:mail@clinuvel.com)

**Australia (Head Office)**, Level 22, 535 Bourke Street, Melbourne, Victoria, 3000, Australia



**Clinuvel Pharmaceuticals Limited**  
**Annual General Meeting**  
**Wednesday, 16 October 2024**  
**Results of Meeting**

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Adoption of Remuneration Report	Ordinary	8,935,582 46.59%	9,941,933 51.84%	301,394 1.57%	1,813,187	9,281,976 47.91%	10,091,433 52.09%	1,813,187	Not Carried
2 Election of Director - Mr Matthew Pringle	Ordinary	23,591,458 94.07%	1,185,951 4.72%	304,394 1.21%	23,712	24,095,185 95.30%	1,189,451 4.70%	23,712	Carried
3 Election of Director - Mr Guy van Dievoet	Ordinary	22,031,963 87.84%	2,743,867 10.94%	305,994 1.22%	23,691	22,391,290 88.56%	2,893,367 11.44%	23,691	Carried
4 Election of Director - Dr Pearl Grimes	Ordinary	22,096,238 93.60%	1,205,726 5.11%	304,394 1.29%	1,499,157	22,599,965 94.92%	1,209,226 5.08%	1,499,157	Carried
5 Re-election of Director - Mrs Susan Smith	Ordinary	19,863,907 80.57%	4,482,250 18.19%	304,394 1.24%	454,964	20,221,634 81.36%	4,631,750 18.64%	454,964	Carried
6 Re-election of Director - Dr Karen Agersborg	Ordinary	21,805,326 87.21%	2,876,313 11.50%	322,988 1.29%	100,888	22,181,647 88.00%	3,025,813 12.00%	100,888	Carried
7 Increase in Non-Executive Director Remuneration Pool	Ordinary	17,790,507 84.81%	2,881,467 13.73%	306,394 1.46%	3,798,488	18,287,901 86.37%	2,884,967 13.63%	3,798,488	Carried
8 Spill Resolution (Conditional Resolution)	Ordinary	2,000,234 10.24%	17,219,659 88.20%	304,394 1.56%	1,467,809	2,003,734 10.16%	17,715,053 89.84%	1,467,809	Not Carried

\* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.

In relation to Resolution 1 Adoption of Remuneration Report, as more than 25% of the votes were cast against this resolution, this constitutes a second strike for the purposes of the Corporations Act 2001 (Cth).